Navigation Links
Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
Date:3/17/2009

l new biological drugs a base period of 12 years of data protection with the right to obtain an additional two years once a further indication for use of the product is approved by the FDA.

Today, strong patents, when they exist, can protect all types of medicines from competition, including protection from generic copies. However, effective patent protection is sometimes unavailable or available only for a very limited period once a new medicine gets to market. In both these situations, patent protection by itself can be insufficient to secure a fair return on the research investments needed to get the new medicine to market - thus risking the system by which new cures and treatments are found. These and other patent shortcomings are magnified for biological drugs because of their relative complexity and the greater uncertainty in how patent laws will eventually apply to them.

In addition to strong patents, "data protection" would offer additional needed protections for innovative biological medicines. Data protection, unlike patents, sets out a consistent, defined period in which copied versions of a new biological drug can only come to market if it follows the same rigorous testing requirements that the innovator undertook to gain FDA approval.

Thus, through an adequate period of data protection, patients and their physicians can be assured of a more complete safety and effectiveness track record before "follow-on" or biosimilar products come to market - important because of consistency and purity concerns. Significantly, Eshoo-Inslee-Barton's approach to data protection is consistent with the earlier Senate-approved approach.

Armitage noted that the biotech industry that creates life-saving biologic medicines boosts the U.S. economy and provides high-paying American jobs. According to the Bureau of Labor Statistics, the biosciences sector is expected to add 69,000 U.S. manufacturing
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
2. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
3. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
4. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
5. GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
8. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
9. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
10. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
11. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... develop proprietary medical food, functional food, and dietary supplement products ... , ... North Brunswick, NJ and ... biotechnology company at the crossroads of foods and pharmaceuticals, and ... to announce the signing of a Memorandum of Understanding (MOU) ...
(Date:12/16/2009)... death from roadside bombs to freeway crashes. Traumatic injury, ... to 44, often overwhelms the body,s natural blood-clotting process. ... a team led by Erin Lavik, a new Case ... doctoral student, James P. Bertram, built synthetic platelets that ... work is published in Science Translational Medicine ., ...
(Date:12/16/2009)... solution by swimming , ... ... U.S. Department of Energy’s (DOE) Argonne National Laboratory and Northwestern ... microgears when suspended in a solution, providing insights for design ... gears are a million times more massive than the bacteria,” ...
(Date:12/16/2009)... 16 Sequenom, Inc. (Nasdaq: SQNM ... Buechler and Mr. David Pendarvis to its board ... ) ,, Kenneth F. Buechler, Ph.D., was president, ... From 1988 to 1994, Dr. Buechler was Biosite,s ... Buechler was a senior research scientist for the ...
Breaking Biology Technology:WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 2WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 3Researchers take the inside route to halt bleeding 2Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
... 1,200 new, jobs within 36 months of initiating operations in its second ... ... St. Jude,Medical, Inc. (NYSE: STJ ) today announced plans to expand ... Industrial Park, which will allow the company to increase its,Puerto Rico operations by ...
... Coulter,Inc. (NYSE: BEC ), a leading developer, ... innovate complex biomedical testing,announced today that Charles Slacik, ... will present at the 2007 UBS Global,Life Sciences ... p.m.,(EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
Other Biology Technology:St. Jude Medical to Expand Puerto Rico Operations 2Beckman Coulter to Present at the UBS Global Life Sciences Conference 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7
(Date:12/16/2009)... iQor, a global provider of business process ... InfoWorld 100 Awards Top 100 IT project of ... the first submission for iQor. ,, "We are honored ... said Vikas Kapoor, president and CEO of iQor. "TeQ21 ... us to work faster, smarter and with the added ...
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin ... safety and finger-based biometric identification solutions, announced ... a Special Shareholder Meeting held today approved ... Division to Interact911 Mobile Systems Inc. Of ... favor and 1.2% were opposed. ,, (Logo: ...
(Date:12/16/2009)... Va., Dec. 9 CSC (NYSE: ... the American Association for Laboratory Accreditation awarded ... (ISO/IEC) 17025:2005 accreditation to the company,s Test ... Identity Labs located in Fairmont, W.Va. The ... laboratory in the world to achieve this ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 1AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 7US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 1US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 3US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 4US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 5US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 6US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 7A crystal ball for brain cancer 3F 54598 1A crystal ball for brain cancer 3F 54598 2A crystal ball for brain cancer 3F 54598 3
... AWRE ) today announced that it has amended and ... of comments and a request from the Securities and Exchange ... range of the tender offer to between $2.20 and $2.60 ... share. Aware has also extended the expiration date for the ...
... Improve Application Processing for Passports and Identity CardsFALLS CHURCH, ... ) today announced that the UK Identity and Passport ... responsible for issuing UK passports and ID cards, has ... services contract to upgrade the IPS application and enrollment ...
... 6, 2009 -- Which is a better strategy, ... conventional cropping more profitable than organic farming? Is ... the University of Wisconsin,s College of Agriculture and ... established the Wisconsin Integrated Cropping Systems Trial (WICST) ...
Other Biology News:Aware, Inc. Amends and Extends Dutch Auction Tender Offer 2Aware, Inc. Amends and Extends Dutch Auction Tender Offer 3Aware, Inc. Amends and Extends Dutch Auction Tender Offer 4CSC Awarded $570 Million IT Services Contract by UK Identity and Passport Service 2